Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
BEIJING MEIKANG GENO-IMMUNE BIOTECHNOLOGY CO., LTD. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 3 distinct examiners and are located within 2 distinct art units. ERIC JASON ROGERS is the busiest examiner, managing 1 pending office action.
The distribution of 3 pending office actions across 3 distinct examiners indicates that each matter is being reviewed by a different person. ERIC JASON ROGERS handles 1 pending office action, matching the workload of the other examiners. The concentration in 2 distinct art units suggests some technical overlap despite the variety of examiners. Practitioners must navigate 3 different examiner perspectives while working within the Biotechnology & Pharmaceuticals field.
Since no single examiner handles more than 1 pending office action, the company cannot rely on a unified negotiation strategy with one individual. However, the use of only 2 distinct art units may provide some consistency in the general examination guidelines applied to the portfolio. This structure requires a balance between individual examiner preferences and a centralized technical strategy within the 2 art units involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROGERS, ERIC JASON | 1 | 57.4% | +32.6% |
| BEANE, RANDALL L | 1 | 32.8% | +36.8% |
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705431 | TISSUE-SPECIFIC PROMOTER AND USE THEREOF | ROGERS, ERIC JASON | — |
| 18557147 | RECOMBINANT COAGULATION FACTOR VIII AND USE THEREOF | BEANE, RANDALL L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705431 | TISSUE-SPECIFIC PROMOTER AND USE THEREOF | ROGERS, ERIC JASON | — |
| 18557147 | RECOMBINANT COAGULATION FACTOR VIII AND USE THEREOF | BEANE, RANDALL L | — |
| 17604360 | CYBB LENTIVIRAL VECTOR, LENTIVIRAL VECTOR-TRANSDUCED STEM CELL, AND PREPARATION METHOD AND APPLICATION THEREOF | JOHNSON, ALLISON MARIE | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705431 | TISSUE-SPECIFIC PROMOTER AND USE THEREOF | ROGERS, ERIC JASON | — | §103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18557147 | RECOMBINANT COAGULATION FACTOR VIII AND USE THEREOF | BEANE, RANDALL L | 1654 | §102§112 | Non-Final OA | — | Pending | Oct 25, 2023 |
| 17604360 | CYBB LENTIVIRAL VECTOR, LENTIVIRAL VECTOR-TRANSDUCED STEM CELL, AND PREPARATION METHOD AND APPLICATION THEREOF | JOHNSON, ALLISON MARIE | 1638 | §103 | Final Rejection | — | Pending | Oct 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial